Physician Views: Biosimilar Remicade Poised for Approval in Europe – Are Rheumatologists and Gastroenterologists Ready?
- Language: English
- Published: July 2013
- Region: Europe
Disease & Therapy Review is meant to be an accurate and efficient executive synopsis of the indications that IPD users look up most frequently. Each report includes epidemiology from the IPD (Incidence and Prevalence Database), treatment data and charts, market data and drug cost when available. The reports are collaboration between our epidemiological specialists and senior market research analysts who each have over 15 years of experience.
Reports currently available include:
- Crohn's Disease
- End Stage Renal Disease
- Heart Failure
- Hepatitis B
- Multiple Sclerosis
- Parkinson's Disease
- Rheumatoid Arthritis
Note: Subscriptions include full access to all DTR reports as well as access to the senior analyst who wrote any of the reports for further questions or comments.
Disease and Therapy Review reports are a compilation of secondary data from the Incidence and Prevalence Database, the 2006 edition of Current Medical Diagnosis and Treatment, and a review of publicly available information including company websites, analyst reports, and key websites. These reports are prepared by experienced market analysts, and are intended to provide a quick snapshot of the key information, including the number of patients who have a health condition, the current treatment approach, cost of therapy, market size, and market trends or issues.
Incidence and Prevalence Database (IPD)
Current Medical Diagnosis and Treatment (CMDT)
The leading annually updated general medical text! CMDT 2006 is the most comprehensive, reliable, and timely reference available to answer common questions in everyday clinical practice. Written in a concise, easy-to-read style, the text covers all aspects of outpatient and inpatient care as well as authoritative descriptions of new developments in medicine. It includes information on over 1,000 diseases and disorders with an emphasis on prevention and cost-effective treatments. CMDT 2006 also features updated information on drug dosages and updated therapeutic options in HIV, including an approach to multi-drug antiretroviral therapies. CMDT is updated annually.
Our senior analysts draw from many other sources depending on the indication.
Yvonne Brill, BS, MBA
Eleven years industry experience (immunology research, regulatory affairs, new product development, and product management/marketing) at Syntex, Nycomed Salutar, and Pharmacyclics. Twelve years experience in market research consulting.
Julie Tompkins, BA, MBA
Twelve years industry experience (analytical chemistry, marketing research, and business and new product planning) at Syntex. Seventeen years experience in market research consulting.
Ann Benham, BS, MBA
Fourteen years primary market research experience in the pharmaceutical, biotechnology, medical device, drug delivery and diagnostics industries, with industry experience at Syntex, Theratech, Genelabs, and Roche Molecular Systems. Two years of experience in market research consulting.
Diane Katzaman, BS, MBA
Twenty years industry experience in product development, marketing management, and market research in telecommunications and healthcare, and two years of experience in market research consulting.
Michon Mahoney, AA
Twenty years industry experience in marketing, market research, new product planning, healthcare economics and forecasting at Syntex, Alza, and Johnson & Johnson. Over fifteen years of experience analyzing market audit data and other secondary data sources.